What VLAW Can Do For You VanDerGinst Law Commitment Meet The VanDerGinst Law Team VanDerGinst Law Testimonials VanDerGinst Law News VanDerGinst Law Community Events Espanol VanDerGinst Law Home Contact VanDerGinst Law
Accident Cases Dangerous Drugs Medical Devices Defective Products
Pollutants Medical Malpractice Consumer Fraud Other Resources
Our Scrapbook Legal Dictionary For Injury Clients Home Safety Tips
Lawyer Values Message to Attorneys The Chicago Lawyer Articles

Merck Highlights VIOXX Appeal, Class Action Waits In The Wings

213627454_cc5d233ee4_m.jpgToday, Merck & Co. announced that a Texas appeals court has ruled in their favor, overturning what had been a $32 million lawsuit. The suit had been brought by the widow of a 71-year-old man who died of a heart attack after taking Merck’s since recalled drug, VIOXX.

As Merck represents it, today’s appeal is a sign of success. They site 12 juries that have ruled in favor of the company, and five juries that have ruled in favor of the plaintiff. But in reality, these twelve so-called victories are vastly overshadowed by the thousands of families involved in class action VIOXX lawsuits, which Merck is expected to settle for $4.85 billion.

This specific appeal was brought because the patient in question, Mr. Leonel Garza Sr., had a long history of heart problems. He began taking VIOXX about a month before he died. Company lawyers argued that because Mr. Garza’s pre-existing condition could easily have caused his death, blaming VIOXX was unsubstantiated.

It’s no surprise that Merck trumpets this as one of many victories. But with $4.85 billion waiting to go out to grieving families, and thousands of lives lost, there is hardly much to celebrate. The appeal is unfortunate for Mr. Garza’s widow, who will never really know the cause of her husband’s death. But an occasional ‘win’ does nothing to change the devastating affects that Merck’s “superdrug” has had on so many families nationwide.

Of course, it is in Merck’s best interest to make a mountain of this molehill appeal. After the appeal was announced, their stock value saw a boost. But long term, investors and consumers will have to ask themselves if holding stock in a company that markets drugs like VIOXX is really worth it. Let’s just wait and see what Merck has to say for themselves when that $4.85 billion class action settlement goes through.

Share this article with others:

Related Posts

Tags: , , , ,

One Response to “Merck Highlights VIOXX Appeal, Class Action Waits In The Wings”

  1. Vioxx Appeal Comes Out In Merck’s Favor | Vlaw Legal & Consumer News Says:

    […] A press release from the company gives the impression that the appeal is just one of many victories. But a major class action lawsuit is in the works, as VIOXX has been estimated to have killed 38,000 people. (Read a more in depth discussion of this issue here.) […]

Leave a Reply




No fee unless we win your accident or injury case. Fields with * must be filled in.

* Full Name
* Email Address
* Phone Number
Cell Number
Address including City, State, & Zip Code
Date of Birth of Injured Person
State Where Accident/Incident Occurred
Describe Accident/Incident and Injuries
Yes, I agree to the VanDerGinst Law disclaimers. Review the disclaimers.
Yes, I would like to receive the VanDerGinst Law Monthly E-Newsletter.
Free Downloadable Law Brochures
VanDerGinst Law Blog
What People Say About VanDerGinst Law
VanDerGinst Law Results
National & Statewide Legal News
AAJ Consumer News
Contact Congress
Online Law Library
The Civil Justice System
The Civil Justice System Know Your Rights The Lawyers Role
Attorneys Help UnSung Heroes Consumer Attorneys Care VLAW Pod-casts